

# **2023**

# **Step Therapy Criteria**

Last Updated: 11/21/2023

HPMS Approved Formulary File Submission 00023576 Version Number 20

# Biophosphates

---

## Products Affected

- *risedronate sodium tablet 35 mg oral*

## Details

<b>Criteria</b>	Trial of Alendronate
-----------------	----------------------

# GLP-1 Agonists

---

## Products Affected

- BYDUREON BCISE AUTO-INJECTOR SUBCUTANEOUS  
2 MG/0.85ML SUBCUTANEOUS
- BYETTA 5 MCG PEN SOLUTION  
PEN-INJECTOR 5 MCG/0.02ML  
SUBCUTANEOUS
- BYETTA 10 MCG PEN SOLUTION  
PEN-INJECTOR 10 MCG/0.04ML

## Details

Criteria	Trial of Metformin
----------	--------------------

---

# ICS/LABA/LAMA

---

## Products Affected

- TRELEGY ELLIPTA AEROSOL POWDER BREATH ACTIVATED 100-62.5-25 MCG/ACT INHALATION
- TRELEGY ELLIPTA AEROSOL POWDER BREATH ACTIVATED 200-62.5-25 MCG/ACT INHALATION

## Details

<b>Criteria</b>	Trial of a LABA or LAMA containing product
-----------------	--

---

# Topical PDE-4 Inhibitors

---

## Products Affected

- EUCRISA OINTMENT 2 %  
EXTERNAL

## Details

<b>Criteria</b>	Trial of topical corticosteroid
-----------------	---------------------------------

**Index**

BYDUREON BCISE AUTO-  
INJECTOR 2 MG/0.85ML  
SUBCUTANEOUS.....2

BYETTA 10 MCG PEN SOLUTION  
PEN-INJECTOR 10 MCG/0.04ML  
SUBCUTANEOUS.....2

BYETTA 5 MCG PEN SOLUTION  
PEN-INJECTOR 5 MCG/0.02ML  
SUBCUTANEOUS.....2

EUCRISA OINTMENT 2 %  
EXTERNAL .....4

*risedronate sodium tablet 35 mg oral*.....1

TRELEGY ELLIPTA AEROSOL  
POWDER BREATH ACTIVATED  
100-62.5-25 MCG/ACT INHALATION ...3

TRELEGY ELLIPTA AEROSOL  
POWDER BREATH ACTIVATED  
200-62.5-25 MCG/ACT INHALATION ...3